Abstract:Three novel platinum‐based antitumor agents containing biotin and fluorinated pyridine ligands were synthesized by combining the conformational advantages of Pt(IV) precursors and picoplatin, and their physicochemical properties and interactions with DNA were investigated, and the in vitro cytotoxic activities of the complexes were also verified. Picoplatin can effectively circumvent cisplatin‐induced resistance through the "steric hindrance effect" of its structure, but there are still problems such as toxicity and side effects, so the search for safer, more efficient platinum analogs is crucial. Here we report three fluorinated pyridine‐containing Pt(IV) complexes employing biotin as an axial ligand to provide targeting functionality. Lipid solubility studies showed that all the synthesized complexes possessed improved lipid‐water partition coefficients, which are beneficial for transmembrane transport of drugs. The DNA binding activity of the compounds was studied using UV titration, fluorescence titration, and PicoGreen staining, demonstrating the presence of potential intercalation and electrostatic interaction binding modes. It probably attributable to planar π‐π interactions provided by the aromatic pyridine ligands. Meanwhile, molecular docking studies showed that the introduction of axial biotin molecules allowed the complexes to effectively target cancer cells, which was simultaneously confirmed by the results of cellular uptake studies. And another docking result showed that the Pt(IV) complexes binds to DNA by minor groove binding. The synthesized complexes exhibited similar cytotoxicity to cisplatin in five cell lines (SW480, HCT116, HepG2, A549 and LO2), with complex 3 being superior to the parent drug, picoplatin.

Novel Platinum(iv) Complexes Conjugated with a Wogonin Derivative As Multi-Targeted Anticancer Agents.

Reversal of Cisplatin Resistance in Human Gastric Cancer Cells by a Wogonin-Conjugated Pt(IV) Prodrug Via Attenuating Casein Kinase 2-Mediated Nuclear Factor-κB Pathways.

Platinum(IV) Complexes Conjugated with Phenstatin Analogue As Inhibitors of Microtubule Polymerization and Reverser of Multidrug Resistance.

Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein

Multitargeted Platinum(IV) Anticancer Complexes Bearing Pyridinyl Ligands as Axial Leaving Groups.

Synthesis and Anticancer Activity of [2-Hydroxy-1,3-diaminopropane-κ2n,n′] Platinum(ii) Complexes

Platinum(IV) Complex-Loaded Nanoparticles with Photosensitive Activity for Cancer Therapy

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity

Synthesis and DNA Interactions Study of Novel Fluorinated Pyridinium Platinum (IV) Complexes with Tumor Targeting Activity

Engineering Novel Amphiphilic Platinum(IV) Complexes to Co-Deliver Cisplatin and Doxorubicin

Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity

Multifunctional platinum(IV) complexes as immunostimulatory agents to promote cancer immunochemotherapy by inhibiting tryptophan-2,3-dioxygenase.

Pt(IV) Prodrugs Containing Microtubule Inhibitors Displayed Potent Antitumor Activity and Ability to Overcome Cisplatin Resistance.

Novel Indole-Chalcone Derivative-Ligated Platinum(IV) Prodrugs Attenuate Cisplatin Resistance in Lung Cancer through ROS/ER Stress and Mitochondrial Dysfunction

Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism

Recent Development in Platinum Complexes with Anticancer Activities and the Underlying Mechanisms

Wogonin Potentiates Cisplatin-Induced Cancer Cell Apoptosis Through Accumulation of Intracellular Reactive Oxygen Species

Synthesis, Characterization, and Antitumor Biological Evaluation of Novel Fluorine‐containing Platinum (IV) Complexes

The New Anticancer Platinum Complex Designed on the Basis of Nucleic Acid

Design, Synthesis and Biological Evaluation of a Novel Platinum(ii) Complex Possessing Bioreductive Groups for Cancer Therapy

Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy